2022
Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era
Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life—Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncology 2022, 8: 1847-1849. PMID: 36264566, PMCID: PMC9585458, DOI: 10.1001/jamaoncol.2022.4666.Peer-Reviewed Original Research
2020
Conducting Goals-of-Care Discussions Takes Less Time Than Imagined.
Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky J, Egorova N, Franco R, Bickell NA. Conducting Goals-of-Care Discussions Takes Less Time Than Imagined. JCO Oncology Practice 2020, 16: e1499-e1506. PMID: 32749930, DOI: 10.1200/jop.19.00743.Peer-Reviewed Original ResearchConceptsGOC discussionsCare discussionsAdvanced solid tumor cancersDifferent hospital typesLength of encounterSolid tumor cancersTotal encounter timePatient ageAdvanced cancerHospital typeRural hospitalsMedicare coveragePatientsCancer progressionOncologistsMultivariate modelEncounter timeVisitsSignificant differencesCancerProgressionMinutesLess timeCommon misperceptionsPrognosisEffects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions.
Bickell NA, Back AL, Adelson K, Gonsky JP, Egorova N, Pintova S, Lin JJ, Kozuch P, Bagiella E, Smith CB. Effects of a Communication Intervention Randomized Controlled Trial to Enable Goals-of-Care Discussions. JCO Oncology Practice 2020, 16: e1015-e1028. PMID: 32374710, DOI: 10.1200/op.20.00040.Peer-Reviewed Original ResearchConceptsElicit patient valuesEnd of lifeAdvanced cancerPatient valuesAggressive careGOC discussionsCare discussionsIntensive care unit admissionHigh care utilizationCare unit admissionMean hospitalizationTraining oncologistsUnit admissionUC patientsAggressive treatmentCare utilizationBlock randomizationCommunication skills trainingOncologistsPatientsCancerCommunication interventionsPrevalenceLife expectancyLast monthImpact of High-Quality Goals-of-Care Discussions on Oncologist Productivity.
Pintova S, Leibrandt R, Smith CB, Adelson KB, Gonsky JP, Egorova N, Franco R, Bickell NA. Impact of High-Quality Goals-of-Care Discussions on Oncologist Productivity. JCO Oncology Practice 2020, 16: e290-e297. PMID: 32048945, DOI: 10.1200/jop.19.00381.Peer-Reviewed Original ResearchConceptsGOC discussionsAdvanced cancerPatient populationCare discussionsPractice settingsDifferent practice settingsOncologist characteristicsStudy patientsCommunity hospitalRural hospitalsPatientsOncologistsHigh-quality goalsRural settingsSignificant differencesHospitalCancerValue unitsHoursSettingPrognosisPopulationCommunication skillsVisits
2018
Does training oncologists to have goals of care discussions affect healthcare utilization among patients with advanced cancer?
Bickell N, Adelson K, Gonsky J, Lin J, Franco R, Egorova N, Smith C. Does training oncologists to have goals of care discussions affect healthcare utilization among patients with advanced cancer? Journal Of Clinical Oncology 2018, 36: 6595-6595. DOI: 10.1200/jco.2018.36.15_suppl.6595.Peer-Reviewed Original Research
2017
Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer
Adelson K, Lee DKK, Velji S, Ma J, Lipka SK, Rimar J, Longley P, Vega T, Perez-Irizarry J, Pinker E, Lilenbaum R. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer. JCO Oncology Practice 2017, 14: jop.2017.023200. PMID: 29206553, DOI: 10.1200/jop.2017.023200.Peer-Reviewed Original ResearchConceptsShort-term mortalityAdvanced cancerChance of deathLife carePrognostic toolNovel prognostic toolObjective prognostic toolSmilow Cancer HospitalDay of admissionElectronic health record dataMedian survival timeSubjective clinical assessmentHealth record dataPositive predictive valueMedian survivalHospitalized patientsMortality predictorsCancer HospitalPrognostication toolsClinical assessmentSurvival timePatientsPredictive valueCancerMortality
2016
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer 2016, 2: 16037. PMID: 28721390, PMCID: PMC5515340, DOI: 10.1038/npjbcancer.2016.37.Peer-Reviewed Original ResearchProgression-free survivalSelective estrogen receptor downregulatorsMetastatic breast cancerER-positive metastatic breast cancerMedian progression-free survivalArm ABreast cancerArm BHormone receptor-positive metastatic breast cancerRandomized phase II trialPhase II trialEstrogen receptor downregulatorsProteasome inhibitor bortezomibPFS ratesII trialConsortium TrialHazard ratioPostmenopausal womenPreclinical modelsInhibitor bortezomibBortezomibCancerProteasome inhibitorsAdditional evaluationTrialsElectronic Intervention to Improve Structured Cancer Stage Data Capture
Cecchini M, Framski K, Lazette P, Vega T, Strait M, Adelson K. Electronic Intervention to Improve Structured Cancer Stage Data Capture. JCO Oncology Practice 2016, 12: e949-e956. PMID: 27650837, DOI: 10.1200/jop.2016.013540.Peer-Reviewed Original ResearchConceptsStaging rateElectronic health recordsCancer stageClinical trial eligibilityElectronic decision supportTrial eligibilityMonths postinterventionCancer stagingPhysician useClinical notesBPA implementationProblem listHealth recordsElectronic interventionMonthsTreatment planningCancerStagingPhysiciansAct methodologyInterventionUnstructured free textHard stopBPAPatientsLactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer
Takabatake Y, Oxvig C, Nagi C, Adelson K, Jaffer S, Schmidt H, Keely PJ, Eliceiri KW, Mandeli J, Germain D. Lactation opposes pappalysin‐1‐driven pregnancy‐associated breast cancer. EMBO Molecular Medicine 2016, 8: 388-406. PMID: 26951623, PMCID: PMC4818749, DOI: 10.15252/emmm.201606273.Peer-Reviewed Original ResearchConceptsPregnancy-associated breast cancerBreast cancerMammary tumorsDeposition of collagenIGFBP-4Mouse mammary glandIGFBP-5Protective effectEffect of lactationPappalysin-1Expression of inhibitorTransgenic micePAPPPregnancyCancerTransient increaseTumor-associated collagen signaturesMammary glandCollagen signaturesTumorsTransgenic expressionLactationProliferative signalingOncogeneCollagenAn electronic intervention to improve structured cancer stage data capture.
Adelson K, Framski K, Lazette P, Vega T, Lilenbaum R. An electronic intervention to improve structured cancer stage data capture. Journal Of Clinical Oncology 2016, 34: 151-151. DOI: 10.1200/jco.2016.34.7_suppl.151.Peer-Reviewed Original ResearchTumor RegistryCancer stagingOutcome analysisClinical trial eligibility determinationDisease-free intervalPalliative care consultationClinical trial eligibilityNumber of patientsElectronic decision supportEligible patientsTrial eligibilityAdvanced diseaseOverall survivalCare consultationsCancer CommitteeFree intervalCancer stageClinical trialsLung measuresClinical notesPatientsRegistry reportingStagingCancerElectronic intervention
2014
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Kalinsky K, Chi D, Lee S, Adelson K, Crew K, Chuang E, Makower D, Hershman D, Califano A, Silva J, Maurer M. Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer. Journal Of Clinical Oncology 2014, 32: tps666-tps666. DOI: 10.1200/jco.2014.32.15_suppl.tps666.Peer-Reviewed Original Research
2011
Hormonal Modulation in the Treatment of Breast Cancer
Adelson K, Germain D, Raptis G, Biran N. Hormonal Modulation in the Treatment of Breast Cancer. Endocrinology And Metabolism Clinics Of North America 2011, 40: 519-532. PMID: 21889718, DOI: 10.1016/j.ecl.2011.05.011.Peer-Reviewed Original ResearchPresurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.
Kalinsky K, Sparano J, Kim M, Crew K, Maurer M, Taback B, Feldman S, Hibshoosh H, Wiechmann L, Adelson K, Hershman D. Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. Journal Of Clinical Oncology 2011, 29: tps147-tps147. DOI: 10.1200/jco.2011.29.15_suppl.tps147.Peer-Reviewed Original Research